A mostrar 1 - 8 resultados de 8 para a pesquisa '"Pharmacokinetics and pharmacodynamics"', tempo de pesquisa: 0.02seg Refinar resultados
  1. 1
    Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

    Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cance... Por Aurelius Omlin (14971513)

    Publicado em 2025
    Assuntos:
    Adic. favoritos
    Na minha lista:
  2. 2
    Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

    Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Por Aurelius Omlin (14971513)

    Publicado em 2025
    Assuntos:
    Adic. favoritos
    Na minha lista:
  3. 3
    Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Por Evan C. Chen (15054014)

    Publicado em 2025
    Assuntos:
    Adic. favoritos
    Na minha lista:
  4. 4
    Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Por Evan C. Chen (15054014)

    Publicado em 2025
    Assuntos:
    Adic. favoritos
    Na minha lista:
  5. 5
    Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Por Evan C. Chen (15054014)

    Publicado em 2025
    Assuntos:
    Adic. favoritos
    Na minha lista:
  6. 6
    Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Por Evan C. Chen (15054014)

    Publicado em 2025
    Assuntos:
    Adic. favoritos
    Na minha lista:
  7. 7
    Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Por Evan C. Chen (15054014)

    Publicado em 2025
    Assuntos:
    Adic. favoritos
    Na minha lista:
  8. 8
    Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Por Evan C. Chen (15054014)

    Publicado em 2025
    Assuntos:
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: